Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company generates news across medical device innovation, regulatory approvals, manufacturing expansions, and healthcare industry developments. As one of the world's largest medical technology manufacturers producing tens of billions of devices annually, BD's announcements often impact healthcare supply chains, public health initiatives, and clinical practice standards.
News coverage for BD typically encompasses product launches of safety-engineered medical devices, FDA clearances for new diagnostic instruments and drug delivery systems, and manufacturing capacity announcements that affect global medical supply availability. The company's role as a major supplier of syringes, needles, IV catheters, and diagnostic equipment means its production decisions can influence healthcare delivery capabilities, particularly during public health emergencies and vaccination campaigns.
Earnings reports reveal performance across BD's three business segments: Medical, Life Sciences, and Interventional. These disclosures provide insight into healthcare spending trends, adoption rates for new medical technologies, and geographic market dynamics across developed and emerging healthcare markets. Regulatory developments, including FDA warning letters, device recalls, or quality system issues, also generate significant news given the company's broad product portfolio and global manufacturing footprint.
Corporate developments such as acquisitions of medical device companies, divestitures of business units, strategic partnerships with pharmaceutical manufacturers, and manufacturing investments shape BD's competitive position. The company's interactions with group purchasing organizations, healthcare systems, and regulatory agencies produce news relevant to understanding healthcare economics and medical device industry dynamics.
Track BD news to monitor developments in medical device innovation, healthcare supply chain updates, regulatory compliance matters, and business performance across the company's medical technology portfolio. Understanding BD's announcements provides context on trends in hospital supply management, clinical diagnostics, and medication delivery technologies.
BD (Becton, Dickinson and Company) (NYSE: BDX) will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020, at 8:00 a.m. ET. A live webcast will be available on the BD corporate website, with a replay accessible for seven days post-event. BD is a global leader in medical technology, dedicated to advancing health through innovative solutions. With a workforce of 65,000, the company aims to improve clinical therapy, diagnostic accuracy, and healthcare efficiency worldwide. For further details, visit www.bd.com/investors.
BD (Becton, Dickinson and Company) has acquired the Medical Business assets of CUBEX LLC, enhancing its medication management solutions. This acquisition integrates CUBEX's MedBank cloud-based software with BD's Pyxis™ Automated Dispensing Cabinets. The move aims to improve patient care across various healthcare settings, addressing challenges like medication diversion and inventory management. Approximately 40 CUBEX employees will join BD. Terms of the deal were not disclosed, but it will not affect BD's fiscal 2021 guidance.
BD (Becton, Dickinson and Company) has received authorization from Health Canada for its rapid SARS-CoV-2 antigen test, part of a government order for 7.6 million tests to enhance COVID-19 testing capabilities. The test provides results in about 15 minutes, enabling quicker decision-making at the point-of-care. Designed to ease the load on labs, this mid-nasal swab test is less invasive than traditional methods. The BD Veritor™ Plus System, already in use for other diagnostics, will support public health efforts across Canada.
BD (Becton, Dickinson and Company) (NYSE: BDX), a key player in global medical technology, announced its participation in two upcoming virtual healthcare conferences. The Stifel 2020 Virtual Healthcare Conference is scheduled for November 16, 2020, at 9:20 a.m. EDT, followed by the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 a.m. EDT. Investors can access live webcasts on the corporate website, with recordings available for at least seven days post-conference.
BD (Becton, Dickinson and Company) reported Q4 2020 revenues of $4.784 billion, a 4.4% increase year-over-year. Despite strong contributions from COVID-19 diagnostics, diluted EPS fell to $0.36, down 20%. The BD Medical segment saw a 4.9% revenue decline, while the Life Sciences segment grew 31.2% due to strong diagnostic sales. The company expects fiscal 2021 revenue growth of high single to low double-digits and adjusted EPS between $12.40 and $12.60, reflecting growth over fiscal 2020.
BD (NYSE: BDX) announced key executive appointments effective January 1, 2021. Patrick Kaltenbach is named executive vice president and chief technology officer, succeeding John DeFord, who will retire. Kaltenbach, with nearly 30 years of R&D management experience, will drive BD's innovation strategy and oversee the 'Innovation and Growth Fund.' Additionally, Dave Hickey is promoted to executive vice president and president of the Life Sciences segment, succeeding Kaltenbach. Both leaders will report to CEO Tom Polen, focusing on enhancing BD's impact in medical technology.
CerTest Biotec and BD (Becton, Dickinson and Company) announced that their VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the BD MAX™ System has received CE marking under the IVD Directive (98/79/EC). This kit enables simultaneous testing for COVID-19, Influenza, and RSV, enhancing diagnostic capabilities during flu season. The BD MAX™ System is already used in numerous European laboratories, providing rapid results within two to three hours. BD's collaboration with CerTest aims to improve diagnostic efficiency and patient care during the winter season.
BD (Becton, Dickinson and Company) celebrates 25 years of partnership with Mercy Ships, announcing a donation of $1 million to support the launch of the Global Mercy, the world's largest NGO hospital ship. This contribution increases BD's total philanthropic investment in Mercy Ships to $2.5 million. The ship, set to sail to Africa in late 2021, features advanced medical facilities and aims to address the severe lack of surgical care, particularly in Africa, where 93% of the 18.6 million annual deaths due to inadequate surgical access occur.
BD (Becton, Dickinson and Company) has received 510(k) clearance from the U.S. FDA for its FACSLyric™ Flow Cytometer combined with the BD FACSDuet™ Sample Preparation System. This integrated system fully automates the sample-to-answer process, enhancing laboratory efficiency by reducing errors and minimizing manual interventions. The FACSDuet provides a walkaway solution that streamlines workflows and improves data integration with laboratory systems. The system is now available as an IVD system in the U.S. and countries recognizing CE-IVD certification.
BD (Becton, Dickinson and Company) announced a live webcast for its fourth fiscal quarter and full fiscal year 2020 earnings conference call on November 5, 2020, at 8:00 a.m. (ET). The earnings press release will precede the call. Investors can access the webcast and related slides on the company's investor website, with a replay available until November 12, 2020. BD operates globally, focusing on advancing health through innovative medical technologies, enhancing care delivery, and supporting health care providers.
FAQ
What is the current stock price of Becton Dickinson & Co (BDX)?
What is the market cap of Becton Dickinson & Co (BDX)?
